Zobrazeno 1 - 10
of 221
pro vyhledávání: '"Shuichi, Mitsunaga"'
Autor:
Shuichi Mitsunaga, Nobuaki Okumura, Toshiki Takei, Toshifumi Takao, Hironobu Tsubouchi, Kohei Nakata, Masafumi Nakamura, Yuji Kitahata, Hideki Motobayashi, Masafumi Ikeda, Masamitsu Nakazato
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract This study aimed to confirm urinary protein fragments in relation to the presence of pancreatic ductal adenocarcinoma (PDAC) via a C-terminal proteomics strategy using exploratory and validation cohorts. Urinary fragments were examined by iT
Externí odkaz:
https://doaj.org/article/58380a3c61fd430ba5dbcdf0542662c5
Autor:
Taro Shibuki, Mitsuhito Sasaki, Shota Yamaguchi, Kanae Inoue, Tomonao Taira, Tomoyuki Satake, Kazuo Watanabe, Hiroshi Imaoka, Shuichi Mitsunaga, Takeshi Fujisawa, Kento Tomizawa, Hidekazu Oyoshi, Masaki Nakamura, Hidehiro Hojo, Masafumi Ikeda
Publikováno v:
Radiation Oncology, Vol 18, Iss 1, Pp 1-4 (2023)
Externí odkaz:
https://doaj.org/article/adb499a96ddf48e9a9e9b5bf2ecc1691
Autor:
Taro Shibuki, Mitsuhito Sasaki, Shota Yamaguchi, Kanae Inoue, Tomonao Taira, Tomoyuki Satake, Kazuo Watanabe, Hiroshi Imaoka, Shuichi Mitsunaga, Takeshi Fujisawa, Kento Tomizawa, Hidekazu Oyoshi, Masaki Nakamura, Hidehiro Hojo, Masafumi Ikeda
Publikováno v:
Radiation Oncology, Vol 18, Iss 1, Pp 1-9 (2023)
Abstract Background Patients with unresectable pancreatic cancer (PC) sometimes experience gastrointestinal bleeding (GIB) due to tumor invasion of the gastrointestinal tract (tumor bleeding); no standard treatment has been established yet for this c
Externí odkaz:
https://doaj.org/article/f5e2e82d53b14455a922f792aac2eb6e
Autor:
Taro Shibuki, Ko Fukushi, Kanae Inoue, Tomonao Taira, Tomoyuki Satake, Kazuo Watanabe, Mitsuhito Sasaki, Hiroshi Imaoka, Shuichi Mitsunaga, Masafumi Ikeda
Publikováno v:
DEN Open, Vol 4, Iss 1, Pp n/a-n/a (2024)
Abstract Patients with unresectable pancreatic cancer often present with duodenal bleeding, a potentially life‐threatening complication. In our case series of six unresectable pancreatic cancer patients with tumor bleeding, we explored the efficacy
Externí odkaz:
https://doaj.org/article/3cc1fad13d954b6cb8b1193fbb4f06d7
Autor:
Hidetaka Suzuki, Shuichi Mitsunaga, Masafumi Ikeda, Takao Aoyama, Kazumi Yoshizawa, Masayuki Yamaguchi, Masami Suzuki, Minoru Narita, Toshikatsu Kawasaki, Atsushi Ochiai
Publikováno v:
Cancer Medicine, Vol 11, Iss 24, Pp 5001-5012 (2022)
Abstract Background Nerve invasion (N‐inv) is an important prognostic factor in pancreatic ductal adenocarcinoma (PDAC). Elucidation of circulating N‐inv stimulators could provide deeper insights and novel perspectives for PDAC therapy. The inter
Externí odkaz:
https://doaj.org/article/efd5f3e361854948abe6a02cbdc5972c
Autor:
Ai Irisawa, Misaki Takeno, Kazuo Watanabe, Hideaki Takahashi, Shuichi Mitsunaga, Masafumi Ikeda
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract Although FOLFIRINOX (l-Leucovorin/5-FU/Irinotecan/Oxaliplatin) is established as one of the standard therapies for patients with metastatic pancreatic cancer, the modified FOLFIRINOX (mFOLFIRINOX) is often used in clinical practice to reduce
Externí odkaz:
https://doaj.org/article/65c01dfb2a5647ad8d10deca7ae7b0bb
Autor:
Tomoyuki Satake, Taro Shibuki, Kazuo Watanabe, Mitsuhito Sasaki, Hiroshi Imaoka, Shuichi Mitsunaga, Motohiro Kojima, Masafumi Ikeda
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a rare subtype of primary liver cancers. Therapeutic strategies for patients with cHCC-CCA are limited, and no standard systemic treatment has been established for unresectable cHCC-CCA. Here,
Externí odkaz:
https://doaj.org/article/07194318a3d7407090c95ccc1982f0f3
Autor:
Hiromichi Nakajima, Kenichi Harano, Tokiko Nakai, Shota Kusuhara, Takehiro Nakao, Chikako Funasaka, Chihiro Kondoh, Nobuaki Matsubara, Yoichi Naito, Ako Hosono, Shuichi Mitsunaga, Genichiro Ishii, Toru Mukohara
Publikováno v:
Breast, Vol 61, Iss , Pp 136-144 (2022)
Background: The previous second-line treatment for HER2-positive metastatic breast cancer were ado-trastuzumab emtansine (T-DM1); however, its activity is decreased in tumors with heterogenous, reduced, or loss of HER2 expression. Trastuzumab deruxte
Externí odkaz:
https://doaj.org/article/d024404aa0a9446f8558c9fcac6f4da6
Autor:
Kazuo Watanabe, Shuichi Mitsunaga, Motohiro Kojima, Hidetaka Suzuki, Ai Irisawa, Hideaki Takahashi, Mitsuhito Sasaki, Yusuke Hashimoto, Hiroshi Imaoka, Izumi Ohno, Masafumi Ikeda, Tetsuo Akimoto, Atsushi Ochiai
Publikováno v:
Cancer Medicine, Vol 9, Iss 9, Pp 3130-3141 (2020)
Abstract Background In the case of liver metastasis (LM), tumors showing the replacement growth pattern (RGP), in which metastatic cells infiltrate and replace hepatocytes with minimal desmoplastic reaction and inflammatory cell infiltration, associa
Externí odkaz:
https://doaj.org/article/f677e50b291445b787ee6bfe1fcf437b
Autor:
Satoru Miura, Tateaki Naito, Shuichi Mitsunaga, Katsuhiro Omae, Keita Mori, Toshimi Inano, Teiko Yamaguchi, Noriatsu Tatematsu, Taro Okayama, Ayumu Morikawa, Takako Mouri, Hisashi Tanaka, Madoka Kimura, Hisao Imai, Takuro Mizukami, Akira Imoto, Chihiro Kondoh, Shinsuke Shiotsu, Hiroyuki Okuyama, Makoto Ueno, Toshiaki Takahashi, Tetsuya Tsuji, Hideki Aragane, Akio Inui, Takashi Higashiguchi, Koichi Takayama
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
Abstract Background Most advanced elderly cancer patients experience fatigue, anorexia, and declining physical function due to cancer cachexia, for which effective interventions have not been established. We performed a phase I study of a new nonphar
Externí odkaz:
https://doaj.org/article/23ab2a263ae1478bbbcac019d360c3f6